Daclatasvir Dihydrochloride

Koarte beskriuwing:

Namme fan API Oanwizing Spesifikaasje Amerikaanske DMF EU DMF CEP
Daclatasvir Dihydrochloride HCV Yn-hûs    


Produkt Detail

Produkt Tags

PRODUCT DETAIL

Beskriuwing

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is in krêftich en oraal aktyfHCV NS5A proteïneinhibitor meiEC50s berik fan 9-146 pm foarmeardere HCV-replikongenotypen.Daclatasvir dihydrochloride is ek inorganysk anion ferfierend polypeptide 1B (OATP1B)enOATP1B3inhibitor meiIC50s fan respektivelik 1,5 µM en 3,27 µM.

IC50& Doel

EC50: 50 pM (HCV-replikon genotyp 1a), 9 pM (HCV-replikon genotyp 1b), 71 pM (HCV-replikon genotype 2a), 146 pM (HCV-replikon genotype 3a), 12 pM (HCV-replikon genotype 33 pM en 4a) HCV-replikon genotyp 5a)[1]
Kd: 8 nM (NS5A33-202) en 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) en 3.27 µM (OATP1B3)[3]

In vitro

Daclatasvir (BMS-790052) toant krêftige remmende aktiviteit foar alle geteste genotypen, mei EC50wearden fariearjend fan 9 pm oant 146 pm.Daclatasvir inhibeart HCV-replikon genotyp 1a, 1b, 2a, 3a, 4a en 5a mei EC50wearden fan respektivelik 50 pM, 9 pM, 71 pM, 146 pM, 12 pM en 33 pM.Daclatasvir is in krêftige ynhibitor fan it JFH-1 genotype 2a ynfekteare firus dat replikearret yn selkultuer (EC)50= 28 oere)[1].Daclatasvir (BMS-790052) bindet strak oan NS5A33-202 en NS5A26-202 mei Kds fan respektivelik 8 nM en 210 nM[2].

Opslach

Poeder

-20°C

3 jier
 

4°C

2 jier
Yn oplosmiddel

-80°C

6 moanne
 

-20°C

1 moanne


Klinyske test

NCT nûmer Sponsor Betingst Begjin Datum

Faze

NCT03369327 Teheran University of Medical Sciences|RojanPharma Pharmaceutical Company Hepatitis C firusynfeksje, antwurd op terapy fan | Human Immunodeficiency Virus 1 jannewaris 2017

Fase 3

NCT03485846 R-Pharm|Almedis Chronische hepatitis C genotyp 1b 27 novimber 2017

Fase 2

NCT01016912 Bristol-Myers Squibb Hepatitis C ynfeksje desimber 2009

Fase 2

NCT01629732 Bristol-Myers Squibb Hepatitis C firus maart 2013

Fase 2

NCT01497834 Bristol-Myers Squibb Hepatitis C Jannewaris 2012

Fase 3

NCT01973049 Bristol-Myers Squibb Hepatitis C desimber 2013

Fase 3

NCT00663208 Bristol-Myers Squibb Chronyske hepatitis C Mei 2008

Fase 2

NCT02576314 Humanity and Health Research Centre|Beijing 302 Hospital Chronyske hepatitis C-ynfeksje Mei 2015

Fase 3

NCT02756936 Genuine Research Center, Egypte | Zeta Pharma Pharmaceutical Industries Sûn febrewaris 2016

Fase 1

NCT02771405 National Hepatology & Tropical Medicine Research Institute | Cairo University Hepatitis C, Chronic | Hepatocellular Carcinoma maart 2016

Fase 3

NCT03706898 Viriom HIV-1-ynfeksje|Hepatyske beheining 1 oktober 2018

Fase 1

NCT02319031 Bristol-Myers Squibb Hepatitis C febrewaris 2015

Fase 3

NCT02124044 National Institutes of Health Clinical Center (CC) | Nasjonaal Ynstitút foar Allergy en ynfeksjesykten (NIAID) | Bristol-Myers Squibb HIV-HCV febrewaris 2014

Fase 2

NCT02551861 Bristol-Myers Squibb Hepatitis C desimber 2015

Fase 2

NCT00859053 Bristol-Myers Squibb Hepatyske ynsuffisjinsje maart 2009

Fase 1

NCT01257204 Bristol-Myers Squibb Hepatitis C firus desimber 2010

Fase 2

NCT03063879 Teheran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Science Hepatitis C, chronike | chronike renale mislearring 1 april 2017

Fase 4

NCT01017575 Bristol-Myers Squibb Hepatitis C ynfeksje desimber 2009

Fase 2

NCT02865369 Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital Chronyske hepatitis C septimber 2016

NCT04070235 De skiednis fan Nanjing Sanhome Pharmaceutical, Co., Ltd. Hepatitis C, chronike 29 maart 2019

Fase 2 | Fase 3

NCT03487848 Bristol-Myers Squibb Hepatitis C | Chronyske hepatitis 18 mei 2018

Fase 2

NCT00904059 Bristol-Myers Squibb Hepatitis C Mei 2009

Fase 1

NCT02107365 Frânsk Nasjonaal Ynstitút foar Sûnens en Medysk Undersyk-Frânsk Nasjonaal Agintskip foar Undersyk nei AIDS en Virale Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb Hepatitis C Virus Genotype 4 Ynfeksje novimber 2013

Fase 2

NCT02397395 Janssen R&D Ierlân Nierfermindering|Nierensykte yn it einfaze Mei 2015

Fase 2

NCT03169348 Assiut University Hepatitis C 1 novimber 2017

Net fan tapassing

NCT02323594 Bristol-Myers Squibb Hepatitis C ynfeksje desimber 2014

Fase 1

NCT03537196 Frânsk Nasjonaal Ynstitút foar Sûnens en Medysk Undersyk - Frânsk Nasjonaal Agintskip foar Undersyk nei AIDS en Virale Hepatitis (Inserm-ANRS) Hepatitis C | Drugsgebrûk | Virale hepatitis C 13 novimber 2018

Fase 4

NCT02103569 Bristol-Myers Squibb Hepatitis C april 2014

Fase 1

NCT02772744 Universiteit fan Zagazig | Universiteit fan Kairo Hepatitis C 1 novimber 2017

NCT01718158 Bristol-Myers Squibb Hepatitis C Jannewaris 2013

Fase 3

NCT02496078 Bristol-Myers Squibb Hepatitis C augustus 2015

Fase 3

NCT01425970 Bristol-Myers Squibb Hepatitis C Mei 2012

Fase 2

NCT01471574 Bristol-Myers Squibb Hepatitis C, Genotype 1 desimber 2011

Fase 3

NCT01573351 Bristol-Myers Squibb Hepatitis C firus Mei 2012

Fase 3

NCT01938625 Janssen R&D Ierlân Hepatitis C, chronike 12 desimber 2013

Fase 2

NCT01492426 Bristol-Myers Squibb Hepatitis C Jannewaris 2012

Fase 3

NCT03480932 Johns Hopkins Bloomberg School of Public Health | Nasjonaal Ynstitút foar Drug Abuse (NIDA) | YR Gaitonde Sintrum foar AIDS Undersyk en Underwiis Hepatitis C, chronike 2 febrewaris 2018

Fase 2 | Fase 3

NCT03163849 Assiut University Chronyske hepatitis c 1 septimber 2019

Fase 3

NCT01581203 Bristol-Myers Squibb Hepatitis C firus Mei 2012

Fase 3

NCT01492504 Bristol-Myers Squibb Hepatitis C 7 febrewaris 2012

NCT03686722 Mohamed Raslan|Ain Shams University|Drug Research Centre, Kairo, Egypte Diabetes mellitus, Type 2 | Hepatitis C | Drug ynteraksjes 9 septimber 2017

Fase 1

NCT02262728 Janssen Research & Development, LLC Hepatitis C, chronike 30 septimber 2014

Fase 2

NCT02349048 Janssen Research & Development, LLC Hepatitis C firus Jannewaris 2015

Fase 2

NCT03882307 Assiut University Hepatitis C, chronike Mei 2020

Iere faze 1

NCT02758509 Parc de Salut Mar Chronyske hepatitis C | Cirrhosis 1 jannewaris 2010

NCT01795911 Bristol-Myers Squibb Hepatitis C maart 2013

Fase 2

NCT03549832 Assiut University | Sohag University | South Valley University HCV Coinfection 1 jannewaris 2018

Net fan tapassing

NCT02161939 Bristol-Myers Squibb Chronyske hepatitis C  

NCT01309932 Bristol-Myers Squibb Hepatitis C maart 2011

Fase 2

NCT01995266 Bristol-Myers Squibb Hepatitis C 28 febrewaris 2014

Fase 3

NCT02640157 AbbVie Chronic Hepatitis C | Hepatitis C Virus | Genotype 3 Hepatitis C Virus desimber 2015

Fase 3

NCT02032875 Bristol-Myers Squibb Hepatitis C maart 2014

Fase 3

NCT02624063 Federale Universiteit fan São Paulo Hepatitis C, chronike desimber 2015

Fase 4

NCT00546715 Bristol-Myers Squibb Chronyske hepatitis C novimber 2007

Fase 1 | Fase 2

NCT01718145 Bristol-Myers Squibb Hepatitis C firus ynfeksje novimber 2012

Fase 3

NCT01616524 Bristol-Myers Squibb Hepatitis C firus (HCV) july 2012

Fase 3

NCT02032901 Bristol-Myers Squibb Hepatitis C Jannewaris 2014

Fase 3

NCT03540212 Ain Shams University Chronyske HCV-ynfeksje 10 desimber 2017

Fase 2 | Fase 3

NCT02097966 Bristol-Myers Squibb Chronyske hepatitis C  

NCT02596880 Teheran Universiteit fan Medyske Wittenskippen Hepatitis C | Cirrhosis septimber 2015

Fase 3

NCT04019717 De bedriuw Atea Pharmaceuticals, Inc. Hepatitis C | Hepatitis C, chronike | Chronyske hepatitis C | Hepatitis C firusynfeksje | HCV-ynfeksje 20 juny 2019

Fase 2

NCT02992457 Tanta Universiteit Hepatitis C Jannewaris 2015

Fase 4

NCT03547895 Zagazig Universiteit Dekompensearre cirrhosis 1 juny 2015

Net fan tapassing

NCT03004625 Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|Nasjonaal Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|Nasjonaal Cheng-Kung University Hospital Hepatitis C novimber 2016

Fase 3

NCT01051414 Bristol-Myers Squibb Hepatitis C ynfeksje april 2010

Fase 2

NCT02309450 Frânsk Nasjonaal Ynstitút foar Sûnens en Medysk Undersyk-Frânsk Nasjonaal Agintskip foar Undersyk nei AIDS en Virale Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb Hepatitis C Virus Genotype 4 Ynfeksje desimber 2014

Fase 2

NCT01628692 Bristol-Myers Squibb|Janssen Research & Development, LLC Hepatitis C firus july 2012

Fase 2

NCT03186313 Egyptysk lever sikehûs | Wadi El Nil sikehûs Hepatitis C septimber 2016

Fase 3

NCT03063723 Tredde oansletten sikehûs, Sun Yat-Sen University Chronyske hepatitis C (steurnis) 1 jannewaris 2016

NCT00983957 Bristol-Myers Squibb Chronyske hepatitis C oktober 2009

Fase 1

NCT01725542 Frânsk Nasjonaal Ynstitút foar Sûnens en Medysk Undersyk-Frânsk Nasjonaal Agintskip foar Undersyk nei AIDS en Virale Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb HCV-HIV Co-ynfeksje desimber 2012

Fase 2

NCT02282709 Stichting foar leverûndersyk Chronyske hepatitis C febrewaris 2014

Fase 3

NCT02032888 Bristol-Myers Squibb Hepatitis C febrewaris 2014

Fase 3

NCT03247296 MTI Universiteit Hepatitis C 28 febrewaris 2017

NCT01389323 Bristol-Myers Squibb Hepatitis C septimber 2011

Fase 3

NCT02556086 Bristol-Myers Squibb Hepatitis C desimber 2015

Fase 2

NCT01741545 Bristol-Myers Squibb Hepatitis C firus 31 maart 2013

Fase 3

NCT01866930 Bristol-Myers Squibb Chronyske hepatitis C-ynfeksje 11 july 2013

Fase 3

NCT02268864 Janssen-Cilag International NV Hepatitis C, chronike Jannewaris 2015

Fase 2

NCT01797848 Bristol-Myers Squibb Hepatitis C juny 2014

Fase 3

NCT03166280 Eman Sayed Hassan Abd Allah | Assiut University Hepatitis C juny 2017

NCT02159352 Bristol-Myers Squibb Hepatitis C juny 2014

Fase 1

NCT01125189 Bristol-Myers Squibb Hepatitis C firus july 2010

Fase 2

NCT03748745 De skiednis fan Nanjing Sanhome Pharmaceutical, Co., Ltd. Drug ynteraksjes 19 novimber 2018

Fase 1

NCT01012895 Bristol-Myers Squibb Chronyske hepatitis C desimber 2009

Fase 2

NCT02565888 Radboud Universiteit Hepatitis C | HIV novimber 2015

Fase 1

NCT02555943 Humanity and Health Research Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University Chronyske hepatitis C-ynfeksje|HBV-koinfeksje|Hepatitis B-reaktivaasje febrewaris 2015

Fase 2 | Fase 3

NCT02304159 Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center Hepatitis C | Cirrhosis Jannewaris 2015

Fase 4

NCT02580474 Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju , Korea|Severance Hospital|Korea University Guro Hospital|Eulji Algemien sikehûs|De Katolike Universiteit fan Korea Hepatitis C febrewaris 2016

Fase 4

NCT02104843 Bristol-Myers Squibb Hepatitis C april 2014

Fase 1

NCT01428063 Bristol-Myers Squibb Hepatitis C firus ynfeksje septimber 2011

Fase 2

NCT02123654 Bristol-Myers Squibb Hepatitis C firus ynfeksje april 2014

Fase 3

NCT02565862 Radboud Universiteit Hepatitis C | Diabetes Mellitus | Ynsulineresistinsje Jannewaris 2016

Fase 1

NCT04211844 Ain Shams University Chronyske hepatitis C 1 oktober 2019

NCT00874770 Bristol-Myers Squibb Hepatitis C ynfeksje juny 2009

Fase 2

NCT03883698 Sanjay Gandhi Postgraduate Institute of Medical Sciences Nierfalen, chronike | Hepatitis C 15 maart 2019

Fase 3

NCT01448044 Bristol-Myers Squibb Hepatitis C desimber 2011

Fase 3

NCT01359644 Bristol-Myers Squibb|Pharmasset Chronyske hepatitis C juny 2011

Fase 2

NCT01842451 Fertex Pharmaceuticals Incorporated Chronyske hepatitis C | CHC | HCV | Hepatitis C juny 2013

Fase 2

NCT02762448 Tainan Municipal Sikehûs Hepatitis c july 2016

NCT02473211 Humanity and Health Research Centre|Beijing 302 Hospital Chronyske hepatitis C-ynfeksje Jannewaris 2015

Fase 2 | Fase 3

NCT01455090 Bristol-Myers Squibb Chronyske hepatitis C 30 novimber 2011

Fase 2

NCT03490097 Ain Shams University Chronyske hepatitis c | Metabolysk syndroom 1 desimber 2017

Fase 2 | Fase 3

NCT01170962 Bristol-Myers Squibb Hepatitis C firus augustus 2010

Fase 2

NCT02333292 Valme University Hospital|Sikehûs del SAS de Jerez|Sikehûs Algemiene Universitario Elche|Sikehûs La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Sikehûs de Figueres|Sikehûs Universitario Puerto Real|Sikehûs Universitario Virgen de la Victoria|Sikehûs Universitario de Cannes | Sikehûs Algemiene Universitario de Alicante|Sikehûs Universitario Araba|Sikehûs Royo Vilanova|Sikehûs Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Sikehûs Universitario Reina Sofia de Cordoba|Sikehûs Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica de Navversidad Universidad Navarra|Sikehûs Universitario San Cecilio|Sikehûs Universitario La Fe|Sikehûs Algemiene Universitario de Valencia|Sikehûs Universitario Infanta Leonor|Sikehûs Universitario de Gran Canaria|Sikehûs Algemiene Universitario Santa Lucía|Centro Penitenciario Alicante 1|Sikehûs Haya Universitario de Carlario | la Luz|Hospital General Universitario de Castellón|Sikehûs Parc Taulí, Sabadell Chronyske hepatitis C-ynfeksje desimber 2014

NCT03200184 Teheran Universiteit fan Medyske Wittenskippen Hepatitis C 1 septimber 2016

Fase 4

NCT03188276 Tredde oansletten sikehûs, Sun Yat-Sen University Chronyske hepatitis C 1 febrewaris 2016

Iere faze 1

NCT01830205 Bristol-Myers Squibb Hepatitis C septimber 2012

Fase 1

 

SERTIFIKAAT

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

KWALITEITS BEHEAR

Quality management1

Foarstel18Kwaliteitskonsistinsjeevaluaasjeprojekten dy't goedkard binne4, en6projekten binne ûnder goedkarring.

Quality management2

Avansearre ynternasjonaal kwaliteitsbehearsysteem hat in solide basis lein foar ferkeap.

Quality management3

Kwaliteitsbegelieding rint troch de heule libbenssyklus fan it produkt om de kwaliteit en therapeutyske effekt te garandearjen.

Quality management4

Professional Regulatory Affairs-team stipet de kwaliteitseasken tidens de oanfraach en registraasje.

PRODUKSJE MANAGEMENT

cpf5
cpf6

Korea Countec Bottled Packaging Line

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italië CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Japan Viswill Tablet Detector

cpf14-1

DCS Control Room

KOMPANJON

Ynternasjonale gearwurking
International cooperation
Ynlânske gearwurking
Domestic cooperation

  • Foarige:
  • Folgjende:

  • Skriuw jo berjocht hjir en stjoer it nei ús